DOI:
10.1055/s-00000134
Diabetologie und Stoffwechsel
LinksClose Window
References
Leiter LA, Bain SC, Hramiak I. et al.
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Cardiovasc Diabetol 2019;
18: 73
We do not assume any responsibility for the contents of the web pages of other providers.